Drug intelligence / Profile preview

S1B-408

Development stage: Phase 2
Lead developer: S1 Biopharma, Inc.
Modality: Small Molecules

Overview

S1B-408 is an investigational proprietary combination drug developed by S1 Biopharma for female orgasmic disorder. Its two active components are described as agents with established safety and efficacy in other central nervous system indications and as having pro-sexual effects individually, but their identities and the specific pharmacology of the combination have not been publicly disclosed. S1B-408 is being evaluated in a non-blinded Phase IIa study in women with orgasmic dysfunction. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06516055))

Other names: S1B 408S-1B 408S 1B 408S1B408S-1B408S 1B408

Targets

DRD2 (Dopamine D2 Receptor)Nicotinic Acetylcholine ReceptorADRA2A (α2A)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on S1B-408.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S1B-408.

Explore the full profile